Alendronate vs placebo | Right Decisions

Right Decisions
Polypharmacy guidance: realistic prescribing
Efficacy (NNT)
By Condition
Back
Osteoporosis
Alendronate vs placebo

Update your RDS mobile app to v4.7.2 to download toolkits even when website is down.

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. You will see that each toolkit has a small QR code icon in the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively update to the latest release - RDS app version 4.7.1 - to see this improvement.

Updating to this latest version of the RDS app is also strongly recommended to get the full benefits of the new resilience arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Study population:

Postmenopausal women

a) For primary prevention average T-score was within 2 standard deviations of the mean for bone density

b) For secondary prevention women who had experienced previous vertebral compression fractures

Comments:

Age range 42-85 but >62 for secondary prevention.

These NNTs apply to the first 5 years of treatment only.

All patients received calcium and vitamin D

Outcome

Duration

NNT

Annualised NNT

Rate of vertebral, non-vertebral or hip fractures (as below) over a 5 year period vertebral primary prevention

60 months (5 years)

Age	NNT
65-69	148
70-74	123
75-79	67
80-84	97
85-89	89
90+	47

Age	NNT
65-69	740
70-74	615
75-79	335
80-84	485
85-89	445
90+	235

Non-vertebral primary prevention

60 months (5 years)

Age	NNT
65-69	104
70-74	67
75-79	59
80-84	42
85-89	32
90+	12

Age	NNT
65-69	520
70-74	335
75-79	295
80-84	210
85-89	160
90+	60

Hip primary prevention

60 months (5 years)

Age	NNT
65-69	23
70-74	118
75-79	50
80-84	27
85-89	11
90+	9

Age	NNT
65-69	118
70-74	590
75-79	250
80-84	135
85-89	55
90+	45